# TB-500 Side Effects: What the Research Reports

> TB-500 side effects from published research: Phase I thymosin beta-4 human data report mild-to-moderate adverse events with no dose-limiting toxicities. Theoretical oncological considerations reviewed.

A reading of the safety and tolerability data from published thymosin beta-4 studies, including Phase I human data, theoretical risks, and the limits of current evidence.

## Is TB-500 Safe? Safety Data in the Literature

The available safety data for thymosin beta-4 and TB-500 derives from Phase I human trials of the full-length 44-amino-acid protein, animal model studies, and in vitro experiments. No published randomized controlled trial has evaluated the safety profile of the TB-500 heptapeptide (Ac-LKKTETQ) in humans specifically.

In the Ruff et al. (2010) Phase I randomized, placebo-controlled study of intravenous thymosin beta-4 in healthy human volunteers, doses from 42 to 1,260 mg were administered — a dose range far in excess of informal human protocols — and no dose-limiting toxicities or serious adverse events were observed [11]. Adverse events were infrequent and characterized as mild to moderate. The pharmacokinetic profile showed dose-proportional responses with a short plasma half-life of 0.95–2.1 hours [11].

A separate Phase I trial of recombinant human thymosin beta-4 (NL005) in healthy Chinese volunteers confirmed this profile across single and multiple daily doses: no serious adverse events, no accumulation after 10 consecutive daily doses, and a minimal anti-drug antibody rate (1/108 single-dose subjects; 1/28 multiple-dose subjects, both resolved at follow-up) [12]. The investigators concluded the compound supports continued development for acute myocardial infarction [12].

These data apply to the full-length thymosin beta-4 protein administered intravenously — not to the shorter TB-500 heptapeptide administered subcutaneously or intramuscularly. The safety profile of the heptapeptide via subcutaneous or intramuscular routes in humans has not been established in published clinical trials.

## Adverse Events Reported in TB-500 Studies

From the published and clinical-adjacent record, the adverse events associated with thymosin beta-4 and TB-500 include:

**Injection-site reactions.** Redness, swelling, and discomfort at the site of injection are the most commonly reported events in informal human reports; these are consistent with any peptide injection and are not specific to TB-500's pharmacology.

**Transient systemic reactions.** Fatigue, mild nausea, and dizziness have been described in informal human contexts. In Phase I IV administration of full-length Tβ4 at doses up to 1,260 mg, adverse events were mild to moderate with no dose-limiting events [11].

**No observed serious adverse events.** Neither of the two published Phase I trials of thymosin beta-4 in humans observed serious adverse events or dose-limiting toxicities [11, 12].

Long-term safety of TB-500 in humans is not established; the published human trials were acute or short-term Phase I safety studies, not multi-year observational studies.

## Theoretical Risks: Angiogenesis and Oncological Considerations

The principal theoretical risk associated with TB-500's pro-angiogenic mechanism is a potential oncological concern: angiogenesis supports tumor growth and metastasis, and a compound that upregulates VEGF and drives new vessel formation could theoretically promote the progression of an undetected or pre-existing neoplasm.

No completed animal carcinogenicity study has demonstrated this risk for thymosin beta-4 or TB-500 specifically. The theoretical concern derives from mechanistic reasoning — pro-angiogenic compounds are generally considered cautiously in oncology contexts — not from observed tumor-promoting events in the published literature [6, 7]. The in vitro and in vivo cardiac studies reviewed above, including the porcine MI model at therapeutic doses, reported no increase in tumor formation [16].

This does not mean the risk is absent; it means the carcinogenicity question has not been formally resolved in published controlled studies. Anyone considering TB-500 use in a clinical or research context would need to weigh this theoretical risk against the absence of carcinogenicity data.

## TB-500 WADA Status and Regulatory Context

TB-500 is prohibited at all times under the WADA Prohibited List, Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. The prohibition applies to both thymosin beta-4 and the TB-500 heptapeptide fragment [1]. Athletes subject to WADA-compliant anti-doping testing who use TB-500 face a potential 2–4 year suspension.

The WADA detection window is approximately 30–45 days post-administration for urine and blood samples analyzed by LC-MS/MS in accredited laboratories [1]. This reflects metabolite accumulation and tissue distribution, not active plasma half-life. The 2012 Ho et al. study established the validated analytical method for detecting Ac-LKKTETQ and its metabolites in equine matrices [1]; this method underlies WADA-accredited anti-doping screening.

TB-500 is not FDA-approved for any human indication. Full-length thymosin beta-4 has been investigated by RegeneRx Biopharmaceuticals under IND for cardiac and corneal indications; the TB-500 heptapeptide fragment is listed in ClinicalTrials.gov under NCT07487363 without published results as of this writing.

---

A velvet-bound digest of the thymosin beta-4 literature — peer-reviewed, gold-ruled, and held by no clinic and no vendor.